Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00306722 · ClinicalTrials.gov registry record · Phase 3
An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Flexible Bronchoscopy
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
NCT00306722 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 250 participants.
The verdict
NCT00306722, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
Study Summary
Very often patients receive medication before a diagnostic, therapeutic, or surgical procedure to help them relax, keep them calm, and to relieve them from pain. This is called procedural sedation. During procedural (mild-to-moderate) sedation, a patient is first given a pain-relief medication (analgesic) and then a medication to help him/her relax and keep him/her calm (sedative). Propofol is the drug commonly used for sedation because it releases immediately into the blood stream and causes fast sedation. AQUAVAN (fospropofol disodium) is made as a slow release version of propofol with a longer duration of effect.
Interventions
- DRUG AQUAVAN® (fospropofol disodium) Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00306722
The ClinicalTrials.gov registry entry for NCT00306722 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AQUAVAN® (fospropofol disodium) Injection is the first listed.
NCT00306722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00306722 about?
NCT00306722 is a clinical study titled "An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Flexible Bronchoscopy". Very often patients receive medication before a diagnostic, therapeutic, or surgical procedure to help them relax, keep them calm, and to relieve them from pain. This is called procedural sedation. During procedural (mild-to-moderate) sedation, a patient is first given a pain-relief medication (anal...
What is the current status of trial NCT00306722?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2006-04. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00306722?
The interventions under investigation include: AQUAVAN® (fospropofol disodium) Injection (DRUG).
Who is sponsoring clinical trial NCT00306722?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.